JPH0551566B2 - - Google Patents

Info

Publication number: JPH0551566B2
Authority: JP; Japan
Prior art keywords: quercetin; reverse transcriptase; virus; acid; antiretroviral
Prior art date: 1987-12-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP32151787A

Other languages

English (en)

Japanese (ja)

Other versions

JPH01163121A (ja

Inventor

Katsuhiko Ono

Masanori Fukushima

Hideo Nakane

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Tsumura and Co

Original Assignee

Tsumura and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-21

Filing date

1987-12-21

Publication date

1993-08-03

1987-12-21 Application filed by Tsumura and Co filed Critical Tsumura and Co

1987-12-21 Priority to JP62321517A priority Critical patent/JPH01163121A/ja

1988-09-12 Priority to EP88907791A priority patent/EP0348509B1/en

1988-09-12 Priority to PCT/JP1988/000919 priority patent/WO1989005141A1/ja

1988-09-12 Priority to AT88907791T priority patent/ATE87204T1/de

1988-09-12 Priority to KR1019890701470A priority patent/KR920003577B1/ko

1988-09-12 Priority to DE8888907791T priority patent/DE3879688T2/de

1989-06-27 Publication of JPH01163121A publication Critical patent/JPH01163121A/ja

1993-08-03 Publication of JPH0551566B2 publication Critical patent/JPH0551566B2/ja

Status Granted legal-status Critical Current

Links

REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 44
ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 22
HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 22
MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 22
229960001285 quercetin Drugs 0.000 claims description 22
235000005875 quercetin Nutrition 0.000 claims description 22
229940124522 antiretrovirals Drugs 0.000 claims description 7
239000003903 antiretrovirus agent Substances 0.000 claims description 7
239000004480 active ingredient Substances 0.000 claims description 2
241001430294 unidentified retrovirus Species 0.000 description 10
102100034343 Integrase Human genes 0.000 description 9
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 9
241000700605 Viruses Species 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
230000000694 effects Effects 0.000 description 8
239000001768 carboxy methyl cellulose Substances 0.000 description 7
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000000203 mixture Substances 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000003826 tablet Substances 0.000 description 6
229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
241000725303 Human immunodeficiency virus Species 0.000 description 5
239000002775 capsule Substances 0.000 description 5
235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
239000008112 carboxymethyl-cellulose Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000008187 granular material Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000000798 anti-retroviral effect Effects 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
229940099112 cornstarch Drugs 0.000 description 3
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
-1 fluidity promoters Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
235000012239 silicon dioxide Nutrition 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 2
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
239000003086 colorant Substances 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000009422 growth inhibiting effect Effects 0.000 description 2
241000411851 herbal medicine Species 0.000 description 2
239000001341 hydroxy propyl starch Substances 0.000 description 2
235000013828 hydroxypropyl starch Nutrition 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
238000000034 method Methods 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000008213 purified water Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229910021380 Manganese Chloride Inorganic materials 0.000 description 1
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000714177 Murine leukemia virus Species 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000015177 Saccharina japonica Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
238000011047 acute toxicity test Methods 0.000 description 1
201000006966 adult T-cell leukemia Diseases 0.000 description 1
ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940024546 aluminum hydroxide gel Drugs 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
235000001465 calcium Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000000748 compression moulding Methods 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000865 liniment Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229910052919 magnesium silicate Inorganic materials 0.000 description 1
235000019792 magnesium silicate Nutrition 0.000 description 1
235000002867 manganese chloride Nutrition 0.000 description 1
239000011565 manganese chloride Substances 0.000 description 1
229940099607 manganese chloride Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000002609 medium Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000008164 mustard oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
229940087306 quercetin 10 mg Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000007873 sieving Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
229940083466 soybean lecithin Drugs 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000011282 treatment Methods 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Landscapes

Pyrane Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP62321517A 1987-12-10 1987-12-21 抗レトロウイルス剤 Granted JPH01163121A (ja)

Priority Applications (6)

Application Number	Priority Date	Filing Date	Title
JP62321517A JPH01163121A (ja)	1987-12-21	1987-12-21	抗レトロウイルス剤
EP88907791A EP0348509B1 (en)	1987-12-10	1988-09-12	Anti-retroviral drug
PCT/JP1988/000919 WO1989005141A1 (en)	1987-12-10	1988-09-12	Anti-retroviral drug
AT88907791T ATE87204T1 (de)	1987-12-10	1988-09-12	Anti-retrovirales arzneimittel.
KR1019890701470A KR920003577B1 (ko)	1987-12-10	1988-09-12	항 레트로바이러스제
DE8888907791T DE3879688T2 (de)	1987-12-10	1988-09-12	Anti-retrovirales arzneimittel.

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP62321517A JPH01163121A (ja)	1987-12-21	1987-12-21	抗レトロウイルス剤

Publications (2)

Publication Number	Publication Date
JPH01163121A JPH01163121A (ja)	1989-06-27
JPH0551566B2 true JPH0551566B2 (id)	1993-08-03

Family

ID=18133451

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP62321517A Granted JPH01163121A (ja)	1987-12-10	1987-12-21	抗レトロウイルス剤

Country Status (1)

Country	Link
JP (1)	JPH01163121A (id)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH037224A (ja) *	1989-03-08	1991-01-14	Tsumura & Co	抗レトロウイルス剤
JP2001226273A (ja) *	2000-02-15	2001-08-21	Maruzen Pharmaceut Co Ltd	抗炎症剤および皮膚化粧料

1987
- 1987-12-21 JP JP62321517A patent/JPH01163121A/ja active Granted

Also Published As

Publication number	Publication date
JPH01163121A (ja)	1989-06-27

Publication	Publication Date	Title
US5521161A (en)	1996-05-28	Method of treating HIV in humans by administration of ddI and hydroxycarbamide
EA025176B1 (ru)	2016-11-30	Комбинация для лечения вич-инфекции
JPH0125A (ja)	1989-01-05	ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物
KR100413312B1 (ko)	2004-01-03	항바이러스 복합약제
SK129999A3 (en)	2000-07-11	Pharmaceutical composition, preparation process and use thereof
US6001828A (en)	1999-12-14	Use of tumor factor inhibitors together with antiviral agents and therapeutic compositions thereof against HIV infection
WO1997037661A1 (fr)	1997-10-16	Medicament de prevention et de traitement des infections virales
JPH0551565B2 (id)	1993-08-03
JPH0551566B2 (id)	1993-08-03
JPH0551567B2 (id)	1993-08-03
US6306901B1 (en)	2001-10-23	Agent for prophylaxis and therapy of diseases
JPH0577649B2 (id)	1993-10-27
JPH03141220A (ja)	1991-06-17	抗レトロウイルス剤
JP3002700B2 (ja)	2000-01-24	抗エイズウイルス剤
JPH0616561A (ja)	1994-01-25	抗レトロウイルス剤
JPH03264530A (ja)	1991-11-25	抗レトロウイルス剤
US7671038B1 (en)	2010-03-02	Method of therapeautic treatments including human immunodeficiency virus (HIV) disease and other conditions in a human host by administering adenine nucleotides
JPH11209282A (ja)	1999-08-03	ベルゲニン及びその誘導体を有効成分とする肝機能改善剤
EP0082667A1 (en)	1983-06-29	Pharmaceutical compositions
KR20010075202A (ko)	2001-08-09	라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제
JP2990015B2 (ja)	1999-12-13	抗ｈｉｖ剤
JPH05301816A (ja)	1993-11-16	抗エイズ剤
AU718325B2 (en)	2000-04-13	Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
JPH08208502A (ja)	1996-08-13	抗エイズウイルス剤の効果増強剤
EP1000622A2 (en)	2000-05-17	Antiviral agents